| Elisa Ellen Aumont, MD | |
|
Mountains Community Hospital, 29101 Hospital Road, Lake Arrowhead, CA 92352-9999 | |
| (909) 336-3651 | |
| Not Available |
| Full Name | Elisa Ellen Aumont |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | Mountains Community Hospital, Lake Arrowhead, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184660318 | NPI | - | NPPES |
| 00G774952 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G77495 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Australian scientists from the Monash Institute of Medical Research have "reprogrammed" adult mouse fat cells and neural cells to become stem cells that can differentiate into a variety of different cells (pluripotency). The cells, called "induced pluripotent stem cells" are nearly identical to the naturally occurring pluripotent stems cells, such as embryonic stem cells, which are highly pluripotent, in short supply and their access restricted in the U.S.
Diabetic patients frequently have lesions on their feet that are very difficult to heal due to poor blood circulation. In cases of serious non-healing infections, a decision to amputate could be made. A new therapeutic approach, presented recently in the Journal of Investigative Dermatology by Canadian researchers affiliated with the University of Montreal Hospital Research Centre, could prevent these complications by promoting wound healing.
The American Medical Association's (AMA) House of Delegates adopted a resolution calling on the AMA to work with the federal government to enact new federal policies to decrease the public's exposure to endocrine-disrupting chemicals (EDCs).
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elisa Ellen Aumont, MD 5000 Hopyard Rd, Suite 100, Pleasanton, CA 94588-3348 Ph: () - | Elisa Ellen Aumont, MD Mountains Community Hospital, 29101 Hospital Road, Lake Arrowhead, CA 92352-9999 Ph: (909) 336-3651 |
News Archive
Australian scientists from the Monash Institute of Medical Research have "reprogrammed" adult mouse fat cells and neural cells to become stem cells that can differentiate into a variety of different cells (pluripotency). The cells, called "induced pluripotent stem cells" are nearly identical to the naturally occurring pluripotent stems cells, such as embryonic stem cells, which are highly pluripotent, in short supply and their access restricted in the U.S.
Diabetic patients frequently have lesions on their feet that are very difficult to heal due to poor blood circulation. In cases of serious non-healing infections, a decision to amputate could be made. A new therapeutic approach, presented recently in the Journal of Investigative Dermatology by Canadian researchers affiliated with the University of Montreal Hospital Research Centre, could prevent these complications by promoting wound healing.
The American Medical Association's (AMA) House of Delegates adopted a resolution calling on the AMA to work with the federal government to enact new federal policies to decrease the public's exposure to endocrine-disrupting chemicals (EDCs).
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
› Verified 3 days ago
John Clarke Hankey, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 29101 Hospital Rd, Emergency Medicine Mountain Community Hospital, Lake Arrowhead, CA 92352 Phone: 909-336-3651 | |
Dr. Walter M Maier, MD,MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 29099 Hospital Road, Suite 112, Lake Arrowhead, CA 92352 Phone: 909-337-3661 Fax: 909-337-3570 |